0000000000355343

AUTHOR

Davide Iacuaniello

showing 3 related works from this author

Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study

2018

Purpose: Patients with Cushing’s disease (CD) experience metabolic alterations leading to increased cardiovascular mortality. Recently, the visceral adiposity index (VAI) has been proposed as a marker of visceral adipose tissue dysfunction (ATD) and of the related cardiometabolic risk. We aimed to evaluate the impact of 12-month pasireotide treatment on cardiometabolic risk in CD patients. Methods: This is a multicentre, prospective, and observational study. Sixteen CD patients, referred to the Endocrine Units of the University Hospitals of Messina, Napoli, Padova, and Palermo (Italy), successfully treated with pasireotide for 12 month have been enrolled. In all patients, we assessed anthro…

MaleEndocrinology Diabetes and MetabolismCardiometabolic risk Cushing’s disease hypercortisolism pasireotide visceral adiposity indexLongitudinal StudieDisease030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyRisk FactorsMedicineLongitudinal StudiesProspective StudiesAdiposityFramingham Risk ScoreCushing’s diseaseCushing’s diseaseMiddle AgedPasireotideDiabetes and MetabolismHeart DiseaseItalyAtherosclerosiObesity AbdominalFemaleSomatostatinHumanAdultmedicine.medical_specialtyWaistHeart DiseasesHypercortisolism030209 endocrinology & metabolismIntra-Abdominal Fat03 medical and health sciencesMetabolic DiseasesInternal medicineDiabetes mellitusCardiometabolic risk; Cushing’s disease; Hypercortisolism; Pasireotide; Visceral adiposity index; Endocrinology Diabetes and Metabolism; EndocrinologyHumansPituitary ACTH Hypersecretionbusiness.industryRisk FactorCushing's diseaseAnthropometryAtherosclerosismedicine.diseasePasireotideCardiometabolic riskMetabolic DiseaseVisceral adiposity indexProspective StudiechemistryObservational studybusiness
researchProduct

The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome

2017

Cushing syndrome (CS) is characterized by increased morbidity and mortality compared to the general population. However, there are patients who have more clinical aggressive forms than others. Aim of the study is to evaluate whether the degree of hypercortisolism, defined by the number of times urinary free cortisol (UFC) levels exceed the upper limit of the normal range (ULN), is related to the worsening of phenotypic features, as well as metabolic and cardiovascular parameters, in a cohort of CS patients. A cross-sectional study was conducted on 192 patients with active CS, consecutively presenting at the outpatients' clinic of the University Hospitals of Ancona, Naples, and Palermo. Pati…

AdultMalemedicine.medical_specialtyPediatricsHydrocortisoneEndocrinology Diabetes and MetabolismUrinary systemCushing hypercortisolismPopulationCushing syndrome severity030209 endocrinology & metabolismGastroenterologySeverity of Illness IndexDexamethasoneUrinary free cortisolSettore MED/13 - Endocrinologia03 medical and health sciencesCushing syndromeYoung Adult0302 clinical medicineEndocrinologyDiabetes mellitusInternal medicineUrinary free cortisolmedicineHumanseducationCushing SyndromeCushing syndrome comorbiditieeducation.field_of_studyS syndromebusiness.industryDegree of hypercortisolismMiddle Agedmedicine.diseaseCross-Sectional Studies030220 oncology & carcinogenesisDexamethasone suppression testCohortFemalebusiness
researchProduct

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”

2019

A phase III study has demonstrated that 6-month pasireotide treatment induced disease control with good safety in 15–26% of patients with Cushing’s disease (CD). The aim of the current study was to evaluate the 6-month efficacy and safety of pasireotide treatment according to the real-world evidence. Thirty-two CD patients started pasireotide at the dose of 600 µg twice a day (bid) and with the chance of up-titration to 900 µg bid, or down-titration to 450 or 300 µg bid, on the basis of urinary cortisol (UC) levels or safety. Hormonal, clinical and metabolic parameters were measured at baseline and at 3-month and 6-month follow-up, whereas tumour size was evaluated at baseline and at 6-mont…

AdultMalemedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and MetabolismUrinary system030209 endocrinology & metabolismDiseaseSomatostatin analoguesCushing’s disease; Medical treatment; Pasireotide; Pituitary tumour; Somatostatin analoguesBody Mass IndexYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusHumansMedicinePituitary NeoplasmsPituitary ACTH HypersecretionAdverse effectAgedmedicine.diagnostic_testbusiness.industryPituitary tumourCushing's diseaseMiddle AgedCushing’s diseasemedicine.diseaseMagnetic Resonance ImagingPasireotidePasireotideTreatment OutcomeItalychemistry030220 oncology & carcinogenesisCushing’s disease Medical treatment Pasireotide Pituitary tumour Somatostatin analoguesFemaleOriginal ArticleWaist CircumferenceSomatostatinbusinessLipid profileBody mass indexMedical treatment
researchProduct